News · 26 weeks99-41%
2025-10-262026-04-19
Mix5290d
- SEC Filings31(60%)
- Other18(35%)
- Analyst1(2%)
- Earnings1(2%)
- Insider1(2%)
Latest news
25 items- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRTozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPDThird positive pivotal Phase III clinical trial of AstraZeneca's IL-33-targeting biologic further demonstrates its benefits in COPD Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the annualized rate of moderate-to-severe COPD exacerbations in the primary population of former smokers and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. In MIRANDA, patients received tozorakimab 300mg or placebo on top of standard of care once every two
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 25-NSE filed by AstraZeneca PLC25-NSE - ASTRAZENECA PLC (0000901832) (Subject)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRIMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancerIMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial IMFINZI plus IMJUDO combined with lenvatinib and transarterial chemoembolization (TACE) showed trend toward improved overall survival Positive high-level results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of prog
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRTozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPDFirst-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that tozorakimab reduced the annualized rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population, which included former and current smokers, and patients across all blood eosinophil* counts and all stages of lung function severity. Tozorakimab was generally well tolerated with a fa
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- INSIDERSEC Form 3 filed by new insider Sharma Mani3 - ASTRAZENECA PLC (0000901832) (Issuer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRAstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against CancerJoshua Jackson is joined by Gritty to take the body check off the ice. AstraZeneca and Joshua Jackson have teamed up as part of a national public health campaign designed to encourage fans to Get Body Checked Against Cancer and be proactive in speaking with their doctor. Joshua Jackson brings a unique cultural relevance to the initiative, resonating with a generation that grew up watching him on screen and is now entering a life stage where conversations about cancer risk and screenings become increasingly important. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310693422/en/Joshua Jackson teams up with Gritty and AstraZen
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRKoselugo approved in Canada for plexiform neurofibromas in adults with neurofibromatosis type 1Approval based on KOMET Phase III trial results which showed 20% objective response rate in tumour size reductionMISSISSAUGA, ON, March 9, 2026 /CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).1 The approval by Health Canada was based on positive results from KOMET, the largest and only placebo-controlled global Phase III trial in this patient population. Data were pr
- PRENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancerBased on DESTINY-Breast05 Phase III trial results which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared with T-DM1 If approved, AstraZeneca and Daiichi Sankyo's ENHERTU has the potential to become a new standard of care in this early breast cancer setting AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with HER2-positive breast cancer who have residual invasive disease after neoadjuvant HER2-targeted treatment. The Food and Drug Administration (FDA) grants Priority Review to
- PRENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast CancerBased on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca's ENHERTU has the potential to become a new standard of care in this early breast cancer setting Daiichi Sankyo (TSE: 4568) and AstraZeneca's (NYSE:AZN) supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization (ISH)+) breast cancer who have residual invasive disease after neoadjuvant HE
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form CERT filed by AstraZeneca PLCCERT - ASTRAZENECA PLC (0000901832) (Filer)